Sander van Deventer
Emeritus hoogleraar Translationele Gastro-enterologie
- Naam
- Prof.dr. S.J.H. van Deventer
- s.j.h.van_deventer@lumc.nl
- ORCID iD
- null
Emeritus hoogleraar Translationele Gastro-enterologie
- Faculteit Geneeskunde
- Divisie 2
- Maag-, Darm- en Leverziekten
Contact
- Peeters, R.; Cuenca-Escalona, J.; Zaal, E.A.; Hoekstra, A.T.; Balvert, A.C.G.; Vidal-Manrique, M.; Blomberg, N.; Deventer, S.J. van; Stienstra, R.; Jellusova, J.; Giera, M.; Hannibal, L.; Spiekerkoetter, U.; Beest, M. ter; Berkers, C.R. & Spriel, A.B. van (2022), Fatty acid metabolism in aggressive B-cell lymphoma is inhibited by tetraspanin CD37, Nature Communications 13(1).
- Sogorb-Gonzalez, M.; Vendrell-Tornero, C.; Snapper, J.; Stam, A.; Keskin, S.; Miniarikova, J.; Spronck, E.A.; Haan, M. de; Nieuwland, R.; Konstantinova, P.; Deventer, S.J. van; Evers, M.M. & Valles, A. (2021), Secreted therapeutics: monitoring durability of microRNA-based gene therapies in the central nervous system, Brain Communications 3(2).
- Genderen, J.G. van; Hof, M. van den; Boer, C.G. de; Jansen, H.P.G.; Deventer, S.J.H. van; Tsimikas, S.; Witztum, J.L.; Kastelein, J.J.P. & Pajkrt, D. (2021), Longitudinal assessment of lipoprotein(a) levels in perinatally HIV-infected children and adolescents, Viruses 13(10).
- Pietersz, K.L.; Plessis, F. du; Pouw, S.M.; Liefhebber, J.M.; Deventer, S.J. van; Martens, G.J.M.; Konstantinova, P.S. & Blits, B. (2021), PhP.B enhanced adeno-associated virus mediated-expression following systemic delivery or direct brain administration, Frontiers in Bioengineering and Biotechnology 9.
- Spronck, E.A.; Valles, A.; Lampen, M.H.; Montenegro-Miranda, P.S.; Keskin, S.; Heijink, L.; Evers, M.M.; Petry, H.; Deventer, S.J. van; Konstantinova, P. & Haan, M. de (2021), Intrastriatal administration of AAV5-miHTT in non-human primates and rats is well tolerated and results in miHTT transgene expression in key areas of Huntington disease pathology, Brain Sciences 11(2).
- Pietersz, K.L.; Martier, R.M.; Baatje, M.S.; Liefhebber, J.M.; Brouwers, C.C.; Pouw, S.M.; Fokkert, L.; Lubelski, J.; Petry, H.; Martens, G.J.M.; Deventer, S.J. van; Konstantinova, P. & Blits, B. (2020), Transduction patterns in the CNS following various routes of AAV-5-mediated gene delivery, Gene Therapy 28.
- Depla, J.A.; Sogorb-Gonzalez, M.; Mulder, L.A.; Heine, V.M.; Konstantinova, P.; Deventer, S.J. van; Wolthers, K.C.; Pajkrt, D.; Sridhar, A. & Evers, M.M. (2020), Cerebral organoids, Molecular Therapy - Methods and Clinical Development 18: 167-175.
- Spronck, E.A.; Liu, Y.P.; Lubelski, J.; Ehlert, E.; Gielen, S.; Montenegro-Miranda, P.; Haan, M. de; Nijmeijer, B.; Ferreira, V.; Petry, H. & Deventer, S.J. van (2019), Enhanced factor IX activity following administration of AAV5-R338L "Padua" factor IX versus AAV5 WT human factor IX in NHPs, Molecular Therapy - Methods and Clinical Development 15: 221-231.
- Spronck, E.A.; Brouwers, C.C.; Valles, A.; Haan, M. de; Petry, H.; Deventer, S.J. van; Konstantinova, P. & Evers, M.M. (2019), AAV5-miHTT gene therapy demonstrates sustained Huntingtin lowering and functional improvement in Huntington disease mouse models, Molecular Therapy - Methods and Clinical Development 13: 334-343.
- Martier, R.; Liefhebber, J.M.; Garcia-Osta, A.; Miniarikova, J.; Cuadrado-Tejedor, M.; Espelosin, M.; Ursua, S.; Petry, H.; Deventer, S.J. van; Evers, M.M. & Konstantinova, P. (2019), Targeting RNA-mediated toxicity in C9orf72 ALS and/or FTD by RNAi-based gene therapy, Molecular Therapy - Nucleic Acids 16: 26-37.
- Keskin, S.; Brouwers, C.C.; Sogorb-Gonzalez, M.; Martier, R.; Depla, J.A.; Valles, A.; Deventer, S.J. van; Konstantinova, P. & Evers, M.M. (2019), AAV5-miHTT lowers huntingtin mRNA and protein without off-target effects in patient-derived neuronal cultures and astrocytes, Molecular Therapy - Methods and Clinical Development 15: 275-284.
- Hof, M. van den; Haneveld, M.J.K.; Blokhuis, C.; Scherpbier, H.J.; Jansen, H.P.G.; Kootstra, N.A.; Dallinga-Thie, G.M.; Deventer, S.J.H. van; Tsimikas, S.; Pajkre, D.; Cohen, S.; Kuijpers, T.W.; Plas, A. van der; Weijsenfeld, A.; Stege, J.S. ter; Kootstra, N.A.; Caan, M.W.A.; Mutsaerts, H.J.M.M.; Majoie, C.B.L.M.; Deinirkaya, N.; Verbraak, F.D.; Schmand, B.; Geurtsen, G.; Mathot, R.A.A.; Wit, F.W.N.M.; Reiss, P.; Teunissen, C.F.; Kuhle, J.; Meijer, J.C.M. & NOVICE Study Grp (2019), Elevated Lipoprotein(a) in Perinatally HIV-Infected Children Compared With Healthy Ethnicity-Matched Controls, Open Forum Infectious Diseases 6(9).
- Miniarikova, J.; Zimmer, V.; Martier, R.; Brouwers, C.C.; Pythoud, C.; Richetin, K.; Rey, M.; Lubelski, J.; Evers, M.M.; Deventer, S.J. van; Petry, H.; Deglon, N. & Konstantinova, P. (2017), AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease, Gene Therapy 24(10): 630-639.
- Miniarikova, J.; Zanella, I.; Huseinovic, A.; Zon, T. van der; Hanemaaijer, E.; Martier, R.; Koornneef, A.; Southwell, A.L.; Hayden, M.R.; Deventer, S.J. van; Petry, H. & Konstantinova, P. (2016), Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease, Molecular Therapy - Nucleic Acids 5.
- Capelleveen, J.C. van; Kastelein, J.J.P.; Zwinderman, A.H.; Deventer, S.J.H. van; Collins, H.L.; Adelman, S.J.; Round, P.; Ford, J.; Rader, D.J. & Hovingh, G.K. (2016), Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses, Journal of Clinical Lipidology 10(5): 1137-1144.
- Hovingh, G.K.; Kastelein, J.J.P.; Deventer, S.J.H. van; Round, P.; Ford, J.; Saleheen, D.; Rader, D.J.; Brewer, H.B. & Barter, P.J. (2015), Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial, Lancet 386(9992): 452-460.
- Ford, J.; Lawson, M.; Fowler, D.; Maruyama, N.; Mito, S.; Tomiyasu, K.; Kinoshita, S.; Suzuki, C.; Kawaguchi, A.; Round, P.; Boyce, M.; Warrington, S.; Weber, W.; Deventer, S. van & Kastelein, J.J.P. (2014), Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects, British Journal of Clinical Pharmacology 78(3): 498-508.
- Maczuga, P.; Verheij, J.; Loos, C. van der; Logtenstein, R. van; Hooijer, G.; Martier, R.; Borel, F.; Lubelski, J.; Koornneef, A.; Blits, B.; Deventer, S. van; Petry, H. & Konstantinova, P. (2014), Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver, Gene Therapy 21(1): 60-70.
- Rooswinkel, R.; Mulder, G.J. & Deventer, S. van (2014), Acquiring orphans, Nature Biotechnology 32(3): 213-216.
- Giniatullina, A.; Boorsma, M.; Mulder, G.J. & Deventer, S. van (2013), Building for big pharma, Nature Biotechnology 31(4): A1-A4.
- Maczuga, P.; Lubelski, J.; Logtenstein, R. van; Borel, F.; Blits, B.; Fakkert, E.; Costessi, A.; Butler, D.; Deventer, S. van; Petry, H.; Koornneef, A. & Konstantinova, P. (2013), Embedding siRNA sequences targeting Apolipoprotein B100 in shRNA and miRNA scaffolds results in differential processing and in vivo efficacy, Molecular Therapy 21(1): 217-227.
- Majowicz, A.; Maczuga, P.; Kwikkers, K.L.; Marel, S. van der; Logtenstein, R. van; Petry, H.; Deventer, S.J. van; Konstantinova, P. & Ferreira, V. (2013), Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery.
- Maczuga, P.; Koornneef, A.; Borel, F.; Petry, H.; Deventer, S. van; Ritsema, T. & Konstantinova, P. (2012), Optimization and comparison of knockdown efficacy between polymerase II expressed shRNA and artificial miRNA targeting luciferase and Apolipoprotein B100, BMC Biotechnology 12: -.
- Majowicz, A.; Marel, S. van der; Velde, A.A. te; Meijer, S.L.; Petry, H.; Deventer, S.J. van & Ferreira, V. (2012), Murine CD4(+)CD25(-) cells activated in vitro with PMA/ionomycin and anti-CD3 acquire regulatory function and ameliorate experimental colitis in vivo, BMC Gastroenterology 12: -.
- Huibregtse, I.L.; Zaat, S.A.; Kapsenberg, M.L.; Silva, M.A.S. da; Peppelenbosch, M.P.; Deventer, S.J.H. van & Braat, H. (2012), Genetically Modified Lactococcus lactis for Delivery of Human Interleukin-10 to Dendritic Cells, Gastroenterology Research and Practice: -.
- Marel, S. van der; Majowicz, A.; Kwikkers, K.; Logtenstein, R. van; Velde, A.A. te; Groot, A.S. de; Meijer, S.L.; Deventer, S.J. van; Petry, H.; Hommes, D.W. & Ferreira, V. (2012), Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis, World Journal of Gastroenterology 18(32): 4288-4299.
- Borel, F.; Han, R.; Visser, A.; Petry, H.; Deventer, S.J.H. van; Jansen, P.L.M.; Konstantinova, P. & Collaboration Reseau Ctr Ressource (2012), Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs, Hepatology 55(3): 821-832.
- Travis, S.; Feagan, B.G.; Rutgeerts, P. & Deventer, S. van (2012), The future of inflammatory bowel disease management: Combining progress in trial design with advances in targeted therapy, Journal of Crohn's and Colitis 6: S250-S259.
- Marel, S. van der; Comijn, E.M.; Verspaget, H.W.; Deventer, S. van; Brink, G.R. van den; Petry, H.; Hommes, D.W. & Ferreira, V. (2011), Neutralizing Antibodies Against Adeno-associated Viruses in Inflammatory Bowel Disease Patients: Implications for Gene Therapy, Inflammatory Bowel Diseases 17(12): 2436-2442.
- Koornneef, A.; Maczuga, P.; Logtenstein, R. van; Borel, F.; Blits, B.; Ritsema, T.; Deventer, S. van; Petry, H. & Konstantinova, P. (2011), Apolipoprotein B Knockdown by AAV-delivered shRNA Lowers Plasma Cholesterol in Mice, Molecular Therapy 19(4): 731-740.
- Strisciuglio, C. & Deventer, S. van (2010), Regulatory T cells as potential targets for immunotherapy in inflammatory bowel disease, Immunotherapy 2(6): 749-752.
- Huibregtse IL, Marietta EV, Rashtak S, Koning F, Rottiers P, David CS, van Deventer SJH & Murray JA (2009), Induction of Antigen-Specific Tolerance by Oral Administration of Lactococcus lactis Delivered Immunodominant DQ8-Restricted Gliadin Peptide in Sensitized Nonobese Diabetic Ab degrees Dq8 Transgenic Mice, Journal of Immunology 183(4): 2390-2396.
- Hommes DW, Erkelens W, Ponsioen C, Stokkers P, Raws E, van der Spek M, Ten Kate F & van Deventer SJ (2008), A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis, Journal of Clinical Gastroenterology 42(5).
- D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van De Mierop FJ, Coche JCR, van der Woude J, Ochsenkuhn T, van Bodegraven AA, van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG & Hommes D (2008), Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial, Lancet 371(9613).
- Zelinkova Z, van Beelen AJ, de Kort F, Moerland PD, van Themaat EVL, Velde AAT, van Deventer SJ, de Jong EC & Hommes DW (2008), Muramyl dipeptide-induced differential gene expression in NOD2 mutant and wild-type Crohn's disease patient-derived dendritic cells, Inflammatory Bowel Diseases 14(2).
- Velde AAT, de Kort F, Sterrenburg E, Pronk I, ten Kate FJW, Hommes DW & van Deventer SJH (2007), Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease, Inflammatory Bowel Diseases 13(3).
- Bleuming SA, He XC, Kodach LL, Hardwick JC, Koopman FA, ten Kate FJ, van Deventer SJH, Hommes DW, Peppelenbosch MP, Offerhaus GJ, Li LH & van den Brink GR (2007), Bone morphogenetic protein signaling suppresses tumorigenesis at gastric epithelial transition zones in mice, Cancer Research 67(17).
- Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, van Deventer SJH, Rutgeerts P & Pearce T (2006), A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease, Gut 55(8).
- Lowenberg M, Verhaar AP, Bilderbeek J, van Marle J, Buttgereit F, Peppelenbosch MP, van Deventer SJ & Hommes DW (2006), Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN, EMBO Reports 7(10).
- Loewenberg M, Tuynman J, Scheffer M, Verhaar A, Vermeulen L, van Deventer S, Hommes D & Peppelenbosch M (2006), Kinome analysis reveals nongenomic glucocorticoid receptor-dependent inhibition of insulin signaling, Endocrinology 147(7).
- van Gemert-Horsthuis K, Florie J, Hommes DW, Lavini C, Reitsma JB, van Deventer SJ & Stoker J (2006), Feasibility of evaluating Crohn's disease activity at 3.0 Tesla, Journal of Magnetic Resonance Imaging 24(2).
- Derijks LJJ, Gilissen LPL, Engels LGJB, Bos LP, Bus PJ, Lohman JJHM, van Deventer SJH, Hommes DW & Hooymans PM (2006), Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease, Therapeutic Drug Monitoring 28(1).
- Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, Van Deventer SJH, Neirynck S, Peppelenbosch MP & Steidler L (2006), A phase I trial with Transgenic bacteria expressing interleukin-10 in Crohn's disease, Clinical Gastroenterology and Hepatology 4(6).
- Zelinkova Z, Derijks LJJ, Stokkers PCF, Vogels EWM, van Kampen AHC, Curvers WL, Cohn D, van Deventer SJH & Hommes DW (2006), Inosine triphosphate pyrophosphatase and thiopurine S-methyltransferase genotypes relationship to azathioprine-induced myelosuppression, Clinical Gastroenterology and Hepatology 4(1).
- Stokkers PCF, Deley M, Van Der Spek M, Verberne HJ, Van Deventer SJH & Hommes DW (2006), Intravenous pamidronate in combination with calcium and vitamin D: Highly effective in the treatment of low bone mineral density in inflammatory bowel disease, Scandinavian Journal of Gastroenterology 41(2).
- Van Balkom BPJ, Schoon EJ, Stockbrugger RW, Wolters FL, Van Hogezand RA, Van Deventer SJH, Oldenburg B, Van Dullemen HM & Russel MGVM (2002), Effects of anti-tumour necrosis factor-alpha therapy on the quality of life in Crohn's disease, Alimentary Pharmacology and Therapeutics 16(6).
- Schreiber S, Campieri M, Colombel JF, van Deventer SJH, Feagan B, Fedorak R, Forbes A, Gassull M, Gendre JP, van Hogezand RA, Lofberg R, Modigliani R, Pallone F, Petritsch W, Prantera C, Rampton D, Seibold F, Vatn M, Zeitz M & Rutgeerts P (2001), Use of anti-tumour necrosis factor agents in inflammatory bowel disease - European guidelines for 2001-2003, International Journal of Colorectal Disease 16(1).
- Bemelman WA, Slors JFM, Dunker MS, van Hogezand RA, van Deventer SJH, Ringers J, Griffioen G & Gouma DJ (2000), Laparoscopic-assisted vs open ileocolic resection for Crohn's disease - A comparative study, Surgical Endoscopy 14(8).
- Managing partner